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Malignancies, prothrombotic mutations, and the risk of venous
thrombosis
Blom JW, Doggen CJM, Osanto S, et al. JAMA 2005;293:715-22.
Conclusion:There is an increased risk of venous thrombosis in patients
with cancer. The risk is greatest in the first few months after diagnosis and in
the presence of distal metastasis. Patients also with Factor V Leiden and
prothrombin 20210A mutations have even higher risk.
Summary: This is a report of the Multiple Environmental and Genetic
Assessment (MEGA) of Risk Factors for Venous Thrombosis Study. MEGA
is a case controlled population based study evaluating risk of venous throm-
bosis with various risk factors. This report details risk of venous thrombosis
with cancer and the joint effects of cancer and selected genetic mutations
predisposing to venous thrombosis. Patients were identified at 6 anticoagu-
lation clinics in the Netherlands betweenMarch 1, 1999, andMay 31, 2002.
Patients included were those 18-70 years of age with a first time diagnosis of
pulmonary embolism or lower extremity deep venous thrombosis. Control
patients, (partners of the patients with venous thrombosis) were also utilized
in the study. Both patients and controls received a questionnaire to evaluate
acquired risk factors for venous thrombosis. Once anticoagulation therapy
had been discontinued for three months, patients and controls were inter-
viewed and blood taken for analysis of Factor V Leiden and prothrombin
20210A mutations.
In patients with malignancy, the overall risk of venous thrombosis was
increased 7 times (odds ratio [OR], 6.7; 95% CI, 5.2-8.6). The highest risk
was present in patients with hematologic malignancies (OR 28.0, 95% CI,
4.0-199.7). Risk was also substantially increased in patient with gastrointes-
tinal cancers (OR 18.9; 95% CI, 4.6-77.8), and patients with pulmonary
malignancies (OR 24.8; 95% CI, 3.4-181.1). Risk was highest in the first
several months following malignancy diagnosis (adjusted OR 53.5; 95% CI,
8.6-334.3). In patients with cancer the presence of distal metastatic disease
further increased the risk of venous thromboembolism (VTE) compared to
patients without metastatic disease (adjusted OR, 19.8; 95% CI, 2.6-149.1).
The combination of cancer and Factor V Leiden mutation increased the risk
of VTE 12 times compared to patients with Factor V Leiden mutation and
no diagnosed malignancy. Results were similar for patients with and without
cancer with respect to the prothrombin 20210A mutation.
Comment: The data raises the question as to whether patients with
cancer should be screened for Factor V Leiden and prothrombin 20210A
mutation and treated with prophylactic anticoagulation therapy if a muta-
tion is present. Also the question arises whether prophylactic anticoagulation
is indicated in patients with malignancies associated with an especially high
risk for VTE. The cost effectiveness of such strategies and the ultimate ability
of such strategies to prolong life or improve quality of life is clear in patients
with cancer who are undergoing surgery or active chemotherapy (ACTA
Haematol 2001;106:73-80). There is currently no data to suggest routine
prophylaxis for VTE in all cancer patients would be effective. However, the
results of the current study suggest certain subgroups of patients with cancer
should be studied more closely for potential benefit of routine VTE prophy-
laxis.
Complications of the Cox-II inhibitors parecoxib and valdecoxib after
cardiac surgery
Nussmeier NA, Whelton AA, Brown MT, et al. N Engl J Med 2005;352:
1081-91.
Conclusion: Patients treated with coronary artery bypass grafting and
who have Parecoxib and Valdecoxib utilized for postoperative pain control
had an increased incidence of postoperative cardiovascular events.
Summary: There is serious concern that, in nonsurgical settings, use of
Cox-II inhibitors increases risk of thromboembolic events long-term. The
authors sought to evaluate the safety of Parecoxib and Valdecoxib after
coronary artery bypass grafting. This was a randomized, double-blind study.
After coronary artery bypass grafting, patients were treated for ten days and
followed for thirty days. The Cox-II inhibitors used in this study were
Valdecoxib (Bextra, Pfizer) and its intravenous prodrug Parecoxib (Dymas-
tat, Pfizer). After coronary artery bypass grafting, patients were randomly
assigned to receive intravenous Parecoxib for at least three days followed by
oral Valdecoxib through day ten or were assigned to be treated with
intravenous placebo followed by oral Valdecoxib, or placebo, for ten days.
There were 1,671 patients enrolled in the study and all patients also had
access to opiate based medications. The primary endpoint was the frequency
of pre-defined adverse events (cardiovascular events, renal failure or dysfunc-
tion, gastroduodenal ulceration, and wound-healing complications).
Compared to the group given placebo alone, the groups given Pare-
coxib and Valdecoxib, placebo andValdecoxib, and placebo andValdecoxib,
all had higher rates of confirmed adverse events (4.0% in the placebo group
versus 7.4% in each of the coxib groups; risk ratio for each comparison, 1.9;
95% CI, 1.1-3.2; P .02). Cardiovascular events including myocardial
infarction, cardiac arrest, stroke, and pulmonary embolism were particular
more frequent among patients given Parecoxib and Valdecoxib (2.0% versus
0.5%; risk ratio 3.7; 95% CI, 1.0-13.5; P .03).
Comment: Previous data on the adverse effects of Cox-II inhibitors has
focused on long- term thromboembolic risk. There has been data to suggest
Cox-II inhibitors could exert significant opiate sparing effects after surgical
procedures. The current study, however, suggests patients with coronary
artery disease who undergo CABG may be adversely impacted by the use of
Cox-II inhibitors to control perioperative pain. While no such data currently
exists to implicate Cox-II inhibitors and increased cardiovascular complica-
tions after peripheral vascular surgery, the current data may imply Cox-II
inhibitors should be avoided in patients undergoing peripheral vascular
surgery as well.
Intensive lipid lowering with atorvastatin in patients with stable coro-
nary disease
LaRosa JC, Grundy SM, Waters DD, and the Treating to New Targets
(TNT) Investigators. N Engl J Med 2005;352:1425-35.
Conclusion: In patients with stable coronary heart disease, intensive
lipid-lowering therapy with 80mg Atorvastatin daily provides additional
clinical benefit beyond that with treatment of 10mg of Atorvastatin per day.
Summary: Recent trials indicate intensive lipid-lowering therapy be-
yond traditionally recommended levels in patients with acute coronary
syndromes provides increased benefit with respect to cardiovascular end-
points compared to traditional lipid-lowering therapy in such patients
(N Engl J Med 2004;50:1495-504, and J Am Col Cardiology 2004;
44:1772-9). This study investigated the safety and efficacy of lowering LDL
cholesterol below 100 mg/dL in patients with stable coronary disease.
Eligible patients were men and women 35-75 years of age who had clinically
evident coronary heart disease. Screening of 18,469 patients took place at
256 sites in 14 countries, with 83.7% of these patients felt to be eligible to
enter the open-label run in period of the study. Of these, 5,461 patients were
excluded after the open label run in phase. Most exclusions were secondary
to failure to meet randomization criteria. There were 10,001 patients
ultimately randomized to receive double-blind treatment with either 10 mg
or 80 mg daily of Atorvastatin. Primary endpoint was occurrence of a first
major cardiovascular event (death from coronary heart disease, nonfatal
non-procedure related myocardial infarction, fatal or nonfatal stroke, or
resuscitation after cardiac arrest). Randomization took place between July
1998 and December 1999.
During treatment mean LDL cholesterol levels were 77 mg/dL with
80 mg Atorvastatin daily and 101 mg/dL with 10 mg Atorvastatin daily.
Persistent elevations in liver aminotransferase occurred in 1.2% of the 80 mg
Atorvastatin daily group versus 0.2% in the 10 mg Atorvastatin daily group
(P  0.001). Eight point seven percent (n  434) of the patients receiving
80 mg of Atorvastatin had a primary endpoint. Ten point nine percent (n
548) of the patients receiving 10mg of Atorvastatin had a primary endpoint.
The absolute reduction in rate of major cardiovascular events was 2.2% with
a 22% relative reduction (hazard ratio, 0.78; 95% CI, 0.69-0.89; P .001).
Overall, mortality did not differ between the two groups. Discontinuation of
treatment based on adverse events occurred in 7.2% of the 80 mg Atorva-
statin group versus 5.3% in the 10mg Atorvastatin group (P .001). There
were five cases rhabdomyolysis (2 in the 80 mg Atorvastatin group and 3 in
the 10 mg Atorvastatin group).
Comment: The safety data for the two doses of Atorvastatin utilized in
this trial are consistent with other large scale trials of this drug (NEngl JMed
2004; 350:1495-504 and Lancet 2003; 361:1149-58). The trial was not
adequately powered to detect differences in risk of death from any cause.
Nevertheless, the study is part of a growing body of evidence suggesting that
lowering LDL cholesterol levels significantly below traditionally recom-
mended values has clinical benefit.
Clinical predictors of transient ischemic attack, stroke, or death within
thirty days of carotid angioplasty and stenting
Kastrup A, Groschel K, Schulz JB, et al. Stroke 2005;36:787-91.
Conclusion: Patients with increased age, recent stroke, or hemispheric
transient ischemic attack (TIA), have higher risk of peri-procedure compli-
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